BofA Raises Price Target on Pfizer (PFE) Following Strong Q1 Results

The pharmaceutical elephantine reported adjusted net per stock of $0.75, 4.17% much than the statement forecast of $0.72, portion gross of $14.5 cardinal exceeded expectations of $13.84 cardinal by 4.77%. Ignoring COVID-related products, Pfizer’s halfway concern accrued by 7% operationally.

BofA remarked that Pfizer’s semipermanent gross CAGR people for 2028-2033 is importantly higher than the consensus. BofA sees gathering this purpose arsenic questionable and perchance skewed toward obesity therapies, wherever the marketplace scenery is precise competitive.

Additionally, Pfizer Inc. (NYSE:PFE) revealed details regarding a 35-valent pneumococcal conjugate vaccine that is acceptable for Phase 1. According to BofA, the lack of supporting information and the capableness to resoluteness macromolecule bearer suppression, a large interest regarding ultra-high valent pneumococcal vaccines, inactive request to beryllium determined.

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products successful the US and internationally. The institution offers medicines and vaccines successful assorted therapeutic areas.

While we admit the imaginable of PFE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.